
    
      This is the first clinical trial developed following the report of the Spanish Competent
      Authority on May 23, 2013, considering the PRP as a medicinal product for human use and
      establishing minimum guarantees required of the product and the process of manufacturing. It
      has been conducted from the perspective of both the trauma and the specialized treatment of
      chronic pain anesthesiologist, and manufacturing the PRP on the premises of a Regional Centre
      for Transfusions, all belonging to the Public Health System and therefore without commercial
      interests.
    
  